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Abstract Despite different efforts made to intervene with
the deadly nature of HIV/AIDS, all attempts remained
unsuccessful due to complexity of the viral host interac-
tions. The solution to HIV-1 pandemic is still to come, thus
to assist the efforts being made to intervene with the deadly
nature of the virus, different factors responsible for the
disease burdens have to be looked into a systematic man-
ner. As a result, the present study aimed to find out the
association of IL-4 VNTR polymorphism with HIV-1
susceptibility and rate of disease progression. Three hun-
dred cases and an equal number of sex and age matched
controls were included for this study. The polymerase
chain reaction assay was utilized to genotype IL-4 VNTR.
The results of this study showed statistically significant
variation among cases and controls in the distribution of
the Rp2/Rp2 genotype (OR = 0.36, 95% CI = 0.18–0.69;
P value = 0.0014) indicating, thereby, a possibility of
reduced risk of HIV-1 susceptibility. Thus, Rp2/Rp2
genotype of the IL-4 might have a role to play in reducing
risk of HIV-1 susceptibility among a north Indian
population.
Keywords HIV/AIDS  IL-4 VNTR  Disease
progression
Introduction
The human immunodeficiency virus (HIV) epidemic, first
documented in the early 1980s has since expanded to
include an estimated 2.7 million cases of infection and 2.0
million HIV related deaths worldwide in the year 2007
alone. Current estimates indicate that 32.5 million persons
worldwide are infected with HIV, and that approximately
89,000 new infections occur each day. Sub-Saharan Africa
remains the most heavily affected region, accounting for
71% of all new HIV infections in 2008 [1]. Since the first
report of HIV infection in India in 1986, the virus has
spread all over the country although there is geographic
variation. There are estimated 5.1 million people infected
with HIV with an overall estimated adult prevalence below
1% [2].
IL-4 is a prototypic member of Th2 cytokines and is a
potent anti-inflammatory cytokine. It reduces the produc-
tion of proinflammatory cytokines and destructive enzymes
by monocytes [3]. The IL-4 gene is located on the long arm
of chromosome 5 (q23–31) in a cluster of other cytokine
genes (IL-3, IL-5, IL-9, IL-13, and IL-15, granulocyte
colony-stimulating factor, and interferon regulatory factor)
[4]. It is also a key T helper-2 cytokine that down regulates
and up regulates CCR5 and CXCR4, respectively, the main
coreceptors for HIV [5]. This gene contains a variable
number of tandem repeat polymorphism located in third
intron. Interons are a primary transcript that is removed by
splicing during RNA processing and is not included in the
mature, functional mRNA. However, genetic polymor-
phisms of interons in IL-4 and IL-1 RA genes have been
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reported to modulate a number of diseases in the literature.
IL-4 VNTR consists of 70-bp repeats in intron-3, a rare
allele with two repeats (Rp1/Rp1) and much rarer with four
repeats (Rp2/Rp2). It is a growth costimulator for B and T
cells, mast cells, erythroid progenitor, and myeloid pro-
genitors. Earlier studies have reported that IL-4 inhibits the
release of inflammatory mediators, such as TNF-a, IL-6,
and IL-1a from activated monocytes. The homozygous
Rp1/Rp1 genotype has been reported to modulate risk of
bladder cancer [6]. Maier et al. [7] reported lack of asso-
ciation of IL-4 interon 3 VNTR polymorphism (Rp1/Rp1
genotype) with type 1 diabetes mellitus. On the other hand
Achyut et al. [8] demonstrated a significant association this
genotype of IL-4 interon 3 VNTR polymorphism with
increased risk of type 2 diabetes mellitus as well as its
associated complication with north Indian population.
During HIV infection the host responds with a complex
series of immune reactions to neutralize invading patho-
gens, repair injured tissues, and promote wound healing
[9]. Excessive production of cytokines, such as TNF, IL-
1b, and high mobility group B1 (HMGB1), however, can
be more injurious than the inciting event, initiating diffuse
coagulation, tissue injury, hypotension and death [10, 11].
The inflammatory response is balanced by anti-inflamma-
tory factors including the cytokines IL-10 and IL-4, soluble
TNF receptors, IL-1 receptor antagonists, and transforming
growth factor (TGF-b).
Soriano et al., reported that variants of host genes are
important determinants of susceptibility to HIV-1 infection
and its rate of progression to AIDS [5]. In determining
important mechanisms for protection from HIV infection,
individuals who remain seronegative despite multiple
exposures to the virus represent an extremely valuable
study population. The observation that in some people
repeated exposure to HIV does not result in infection could
be explained in several ways. First, low viral loads or the
presence of replication-defective virus strains in the pri-
mary partner could result in a reduced rate of transmission.
Second, resistance to infection in an exposed uninfected
individual may be caused by the absence or reduced sus-
ceptibility of target cells. Finally, protection from infection
may be mediated by HIV-specific antibodies or cells that
are capable of inhibiting infection and/or viral spread.
Based on the latter mechanism, repeated exposures could
potentially lead to enhancement of antiviral immunity,
functioning much like a booster vaccination [12].
Several findings underscore the potential importance of
humoral immune responses in protection against HIV
infection. Macaques can be protected against intravenous
and mucosal viral challenge following passive transfer of
neutralizing antibodies against the SIV-HIV chimeric
virus, SHIV [13–15]. In addition, circulating antibodies
against the viral core antigen p24 can be detected shortly
after infection and may assist in the control of viral repli-
cation in vivo [16]. IL-4 as one of the Th2-type anti-
inflammatory cytokines is involved in inducing humoral
immunity and plays a role in inducing IgG1 antibodies [17]
and thus IL-4 VNTR could be considered as a candidate
gene to be studied to evaluate its effect on HIV suscepti-
bility and its progression to AIDS. Thus, we hypothesized
that IL-4 as one of the antiinflammatory cytokine genes
could have positive role in reducing HIV susceptibility and
rate of disease progression among north Indian seropositive
patients.
The aim of the present study was to analyze the asso-
ciation of IL-4 VNTR polymorphism on HIV/AIDS sus-
ceptibility and disease progression on north Indian
seropositive patients.
Materials and methods
Blood samples of 300 HIV patients were collected in
EDTA-anticoagulated tube from the Post Graduate Insti-
tute of Medical Education and Research, Chandigarh, all of
them from north Indian population. Inclusion criteria for
collecting blood samples included all patients who were
HIV seropositive, had never started highly active antiret-
roviral treatment (HAART) and their age ranged between
18 and 60 years. Seropositive patients under HAART
treatment were excluded from the study. An equal number
of age and sex matched control samples were collected
from the same institute. An inclusion criterion for recruit-
ing control samples was being seronegative for HIV-1 test
and age ranged between 18 and 60 years. Informed consent
was obtained from both cases and controls as per the
approved guidelines of the ethical committee of Post
Graduate Institute of Medical Education and Research,
Chandigarh. While the detailed history of each patient was
obtained from patients’ record, interviews were conducted
to get relevant information from controls. This study was
approved by the ethical committee of the Post Graduate
Institute of Medical Education and Research, Chandigarh.
Genotyping of IL-4 interon 3 VNTR
Genomic DNA was extracted from peripheral blood lym-
phocytes by the standard phenol- chloroform method. The
IL-4 VNTR polymorphism of 70 bp was amplified using
primers forward 50-AGGCTGAAAGGGGGAAAGC-30and
reverse 50-CTGTTCACCTCAACTGCTCC-30. The PCR
amplification was performed in 25 ll volume containing
100 ng of genomic DNA, 0.2 mM of mixed dNTP,
20 pmol of each primer 1.5 U Taq polymerase, 109 KCl
and 1.5 mM MgCl2. The amplification conditions utilized
were initial denaturation of 950 C for 5 min followed by 30
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cycles of each with denaturation at 95C for 45 s, 65C for
45 s, 72C for 10 s, and a final extension of 72C for
7 min. Alleles of 183 bp (two repeats) and 253 (three
repeats) were designated as RP1 and RP2, respectively and
were analyzed by resolving on 2% agarose gel electro-
phoresis [18] (Fig. 1).
Statistical analysis
Relevant data of cases such as age, sex, CD4 count,
transmission route, occupation, type and number of
opportunistic infections were tabulated to compute the
association with the host genetic factors. However, the
control samples in this study were healthy and only their
age, sex and sexual behavior were tabulated. The effect and
association of the IL-4 VNTR polymorphism on HIV sus-
ceptibility and disease progression was analyzed by com-
puting odds ratio (OR) and 95% confidence interval (CI).
The statistical analysis was performed using Epi-Info
software (Epi-Info, version 3.5.1. Center for Disease
Control and Prevention, Atlanta, GA, USA, August 13,
2008) and software SPSS version 11.5 (SPSS, Chicago,
IL). Chi square (v2) test was utilized to check for the
Hardy–Weinberg’s equilibrium. Significance was set at
P \ 0.05 except for stage and genotype interaction where
significance was set at P \ 0.01.
Results
The demographic characteristic of study subjects is given
in Table 1. Three hundred cases and age and sex matched
controls had participated in this case control study. There
was no significant variation in the mean age of study
subjects. The mean age of cases was 35.23 ± 8 and that of
controls, it was 36.17 ± 10. The number of women in
cases and controls were 107 (35.7%), 105 (35%) respec-
tively. Among 300 HIV seropositive cases, 26 (8.7%) were
labourers, 55 (18.3%) were farmers, 65 (21.7%) drivers and
Fig. 1 PCR-VNTR
representative agarose gel
picture of IL-4 gene of HIV
seropositive subjects
Table 1 Demographic characteristics of study subjects
Cases Controls P value
Mean age ± SD 35.23 ± 7.6 36.17 ± 10.0 0.197*
Place
Urban 96 (32%) 106 (35.3%)
Rural 214 8%) 196 (64.7%)
Sex
Male 193 195
Female 107 105 0.93*
Transmission route in cases
Heterosexual 277
Needle sharing 4
Blood donation 5
Homosexual 1
Unknown 13
Mean of CD4 count at each
stage of cases
I 498
II 384
III 259
IV 116
Occupation of cases
Laborers 26
Farmers 55
Truck driver 65
House wives 89
Others 65
* P [ 0.05
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65 (21.7%) working on other different sectors and 89
(29.70) were house wives. When the transmission route of
HIV was studied, heterosexual transmission accounted for
92.3% of the transmission followed by contaminated nee-
dle 1.7 and unidentified transmission which accounted
1.3% only. Acquiring HIV during blood transfusion and
men who had sex with men (MSM) accounted 1.7 and
0.63% respectively. Cases belonging to the unknown cat-
egory were involved in more than one possible routes of
transmission and did not exactly know the source of their
infection. Cases were tabulated regarding their marriatal
status. Of all 107 women cases, 12 (11.2%) of them were
not married. Similarly, of all the 193 males, only 23
(11.9%) were unmarried. Among 95 married women, 18
lost their spouses (all of them by HIV, except one). Among
170 married men, 20 lost their spouses by HIV/AIDS, 20 of
the spouses were seronegative, 85 seropositive and the
serological status of the remaining 45 male spouses were
not known.
As per the WHO staging guideline cases at all the four
stages of HIV/AIDS were found. Of all the 300 seroposi-
tive cases, 27 (9%) were at stage I, 54 (18%) at stage II, 73
(24.3%) at stage III and 146 (48.7%) were at stage IV of
the disease. The mean CD4 counts for stages I, II III and IV
were 498.37, 383.87, 258.87 and 115.71 respectively.
The Hardy–Weinberg’s equilibrium was analyzed by
using v2 test. Genotype and allelic frequencies were in line
with the Hardy–Weinberg’s equilibrium P [ 0.05. The
percentage of the IL-4 interon 3 VNTR genotype distri-
bution for both cases and controls is given in Table 2. The
frequency of Rp1/Rp1 in cases was 12.7% as compared to
5.3% in controls. The frequency of heterozygous genotype
Rp1/Rp2 was greater in cases (33.3%) from that in controls
(31.3%). On the other hand, the homozygous Rp2/Rp2
genotype was smaller in cases (54%) than that in controls
(63.3%). The heterozygous Rp1/Rp2 and the homozygous
Rp2/Rp2 genotype showed statistically reduced risk for
susceptibility of HIV with OR 0.45, 95% CI 0.22-0.90
and OR 0.36, 95% CI 0.18–0.69, respectively with
P value \ 0.005. Of all the 27 cases at stage I, 9 (59.3%)
were having Rp2/Rp2, on the other hand of all 146 sero-
positive cases at stage IV, only 77 (51.4%) were having the
Rp2/Rp2 genotype. Detailed genotype distribution and
stages of the disease is summarized in Table 3.
When disease progression and genotype frequency was
computed, it was found that of all the 4 patients who were
at stages II and III after 10 years of seroconversion all of
them possessed Rp2/Rp2 genotype and they remained to be
long term non progressors (LTNP) after 10 years of sero-
conversion. No long term non progressors were found with
the other two genotypes. Time of progression with respect
to genotype frequency is given in Table 4.
Discussion
In the present study the genotype frequency of Rp2/Rp2
was associated with statistically significant reduced risk of
HIV susceptibility (OR = 0.36, 95% CI 0.18–0.69, with
P value 0.0014. Moreover, all of the 4 long term non
progressors (those who did not attain stage IV of AIDS
after 10 years of seroconversion) possessed this genotype,
which was 100% availability and no long term non pro-
gressor was observed with other genotypes indicating the
role of Rp2/Rp2 genotype in decreasing the risk of HIV
susceptibility and rate of disease progression.
IL-4 and its receptor IL-4R are very important candidate
genes that affect susceptibility to HIV infection and its
progression to AIDS due to two reasons. First, apart from
its effects on B cells to induce Ig isotype switching to IgE,
IL-4 induces differentiation of CD4? Th cells into Th2
cells, which, in turn, are characterized by production of IL-
4 and lack of interferon c (IFN-c) production. Th1 cells are
characterized by production of IFN-c and absence of IL-4
production. In addition, IL-4 inhibits generation of Th1
cells, while IFN-c inhibits generation of Th2 cells [19, 20].
Though the exact function of the Rp1/Rp2 interon 3
polymorphism is not known [21], Sei et al. [16] showed
that higher virus replication correlated with increased IL-4
levels in lymph nodes from infected children. Moreover,
there existed a report that IL-4 has differential effects on
the expression of CCR5 and CXCR4 and that it also stim-
ulates intracellular pathways leading to increased HIV-1
production [22]. Contrary to this, higher expression of IL-4
Table 2 Genotype and allelic
frequency of IL-4 VNTR among
the study subjects
OR was computed using Epi
Info version 3.5.1. (center for
disease control and prevention)
Cases Controls OR (95% CI) P value
IL-4 genotypes
Rp1/Rp1 38 (12.7%) 16 (5.3%) Ref. 1.0
Rp1/Rp2 100 (33.3%) 94 (31.3%) 0.45 (0.22–0.90) 0.021
Rp2/Rp2 162 (54.0%) 190 (63.3%) 0.36 (0.18–0.69) 0.0014
Allelic frequency
R1 0.3 0.21 1.0 Ref
R2 0.7 0.79 0.62 (0.31–1.24) 0.19
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was reported to be associated with a better prognosis in
Thai population [23]. At present, the reason for the dis-
crepancy among different studies is not clear, but it may be
due to the differences in study design (sero-conversion/
crosssectional, marker/endpoint of disease progression,
duration of follow-up, etc.) or difference in the frequency
of the genotypes. However, allele Rp2 was reported to have
a protective role in autoimmune diseases [23]. Even if, a
multitude of factors, including immunological, genetic,
viral and environmental, can potentially contribute to the
rate of HIV disease progression [24], it could be inferred
from this study that IL-4 VNTR as a host genetic factor
seems to have a greatest role in reducing disease progres-
sion and susceptibility. It is stated that HIV infection
stimulates immune activation and the latter too activates
the former. HIV-infected individuals display elevated
markers of activation and/or apoptosis on CD8? and
CD4? T, as well as B cells, NK cells and monocytes
[25–28]. On the other hand, it is demonstrated that high
levels of proinflammatory cytokines, such as tumor
necrosis factor alpha (TNFa), interleukin 6 (IL-6) and
interleukin 1 beta (IL-1b) in both plasma and lymph nodes,
are observed from the early stages of HIV-1 infection
[29–31] and facilitates disease progression to AIDS via
activation of viral replication.
From the results of the present study, it is possible to
conclude that IL-4 VNTR Rp2/Rp2 genotype may have
likely a role to play in increasing IL-4 level in the serum
that antagonizes the level of proinflamatory cytokines that
in turn reduces viral activation and replication, as a result,
rate of disease progression could be slower. This could be
strengthened by the adverse effect of immune activation in
HIV pathogenesis that accounted for the observations
linking more rapid disease progression in Kenyan prosti-
tutes with frequent inter current infections and related
immune activation [32]. Moreover, it has been stated that
the immune activation caused by HIV is a persistent
chronic hyperactivation of both CD4 and CD8 T cells.
Activated by strander CD4 T cells that appear as a result of
HIV replication may be more sensitive to HIV infection
Table 3 Genotype distribution
in respect to each stage of HIV/
AIDS and relative OR
OR was computed using Epi
Info version 3.5.1. (center for
disease control and prevention)
* P value less than 0.05 and set
as significant
Stages of HIV Genotypes of IL-4 n/c OR (95% CI) P
I Rp1/Rp1 3/16 1.0 Ref –
Rp1/Rp2 8/94 0.50 (0.14–1.70) 0.37
Rp2/RP2 16/190 0.49 (0.16–1.54) 0.20
II Rp1/Rp1 8/16 1.0 Ref –
Rp1/Rp2 15/94 0.32 (0.10–0.98) 0.03
Rp2/RP2 31/190 0.33 (0.12–0.92) 0.03
III Rp1/Rp1 14/16 1.0 Ref –
Rp1/Rp2 19/94 0.23 (0.09–0.60) 0.001*
Rp2/RP2 40/190 0.24 (0.10–0.57) 0.00050*
IV Rp1/Rp1 13/16 1.0 Ref –
Rp1/Rp2 58/94 0.76 (0.32–1.82) 0.64
Rp2/RP2 75/190 0.49 (0.21–1.13) 0.10
Table 4 Frequency of IL-4
VNTR genotype and time of
HIV progression to AIDS
Year after
sero conversion
Genotypes Stage I Stage II Stage III Stage IV
1–2 Rp1/Rp1 1 3 9 7
Rp1/Rp2 3 5 6 20
Rp2/Rp2 3 10 18 25
2–5 Rp1/Rp1 2 2 4 5
Rp1/Rp2 5 10 11 34
Rp2/Rp2 11 16 18 42
6–10 Rp1/Rp1 3 1
Rp1/Rp2 2 3
Rp2/Rp2 2 2 3 8
[10 Rp1/Rp1 1
Rp1/Rp2 1
Rp2/Rp2 3 1
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and may thereby, create positive feedback mechanism,
resulting in further enhancement of HIV replication [33].
As far as our knowledge goes, this is the first case
control study that attempted to evaluate the association of
IL-4 VNTR polymorphism on HIV/AIDS, and thus, it is
hardly possible to provide clear cut explanations as to why
the RP2/RP2 genotype reduces the risk for susceptibility
and disease progression. As a result further studies on the
role of IL-4 VNTR polymorphism in relation to HIV/AIDS
are warranted with large cohort on different ethnic back-
grounds by considering exposed and uninfected control
groups. Furthermore, the role and effect of IL-4 VNTR
polymorphism needs to be confirmed through in vivo
expression on biological animals, so that the function of
each allele could be explained and understood. Since this is
the first report on IL-4 VNTR polymorphism and HIV/
AIDS, shortage of information on IL-4 VNTR polymor-
phism and HIV/AIDS made the explanation of the Rp2/Rp2
genotype association with protective role not to be precise.
Indeed one of the draw backs of the present study was
inability to recruit exposed and non infected individuals as
control groups; however, small sample size and unwilling
of these study subjects to participate for this study short-
ened the study from being completed. This study is part of
our continuing studies on impact of gene polymorphism on
HIV-1 disease progression to AIDS among north Indian
seropositive patients [34].
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